

How *Mesp1* makes a move

Robert G. Kelly

Aix-Marseille University, Centre National de la Recherche Scientifique, Institut de Biologie du Développement de Marseille UMR 7288, 13288 Marseille, France

The transcription factors *Mesp1* and *Mesp2* have essential roles in the migration and specification of multipotent progenitor cells at the onset of cardiogenesis. Chiapparo et al. (2016. *J. Cell Biol.* <http://dx.doi.org/10.1083/jcb.201505082>) identify common *Mesp* functions in fate specification and *Mesp1*-specific targets controlling the speed and direction of progenitor cell migration.

The vertebrate heart forms from multipotent cardiovascular progenitor cells that are specified at gastrulation as they migrate from the primitive streak in the posterior region of the embryo to the anterior lateral mesoderm (Fig. 1). Once they reach this region, cardiac progenitor cells differentiate in the cardiac crescent, rapidly followed by the formation of a linear heart tube. Addition of late-differentiating progenitor cells from the second heart field drives subsequent heart tube elongation, accompanied by rightward looping and the onset of chamber morphogenesis.

The earliest sign of cardiovascular development in the developing mouse embryo is transient expression of the bHLH transcription factor *Mesp1* in the primitive streak (Saga et al., 2000). Although cardiac specification and differentiation occur in the absence of *Mesp1*, the migration of cardiovascular progenitor cells is delayed, impairing the formation of a single linear heart tube. Transcriptional up-regulation of the neighboring and paralogous gene *Mesp2*, coexpressed with *Mesp1* during gastrulation, suggests there is functional redundancy between these factors in cardiac specification and differentiation. This was confirmed by the absence of cranial and cardiac mesoderm in *Mesp1 Mesp2* double mutant embryos (Kitajima et al., 2000). Further studies in chimeric embryos revealed that *Mesp1 Mesp2* double mutant cells do not contribute to the developing heart, indicating a cell autonomous role in cardiac specification. Genetic lineage tracing using Cre recombinase has shown that *Mesp1*-expressing progenitor cells give rise to all cardiac cell types, including myocardium, the endocardial lining of the heart, and the outer epicardial layer. In addition, the *Mesp1* lineage contributes to endothelial cells, smooth muscle, and cranial and extraembryonic mesoderm (Saga et al., 2000). Recently, clonal analysis has revealed that these diverse fates reflect *Mesp1* activation in temporally and molecularly distinct progenitor cell populations. These cell populations contribute sequentially to different cranial and cardiovascular derivatives, including endocardial or myocardial cells of the linear heart tube and, later, multipotent cardiopharyngeal mesoderm, which gives rise to both second heart field and head muscle progenitor cells (Lescroart et al., 2014). The upstream role of *Mesp1* in cardiogenesis is conserved across chordates. The single

ascidian *Mesp* gene is essential for specification of the cardiopharyngeal lineage, which gives rise to the heart and pharyngeal muscles in *Ciona*, and regulates the genetic program controlling cardiopharyngeal progenitor cell migration (Satou et al., 2004; Christiaen et al., 2008).

Differentiating pluripotent embryonic stem (ES) cells provide a powerful system in which to dissect the mechanisms that underlie early fate decisions and have been used extensively to study the onset of cardiac differentiation. The analysis of *Mesp1* function and targets during ES cell cardiac differentiation has provided molecular insights into how *Mesp1* rules the cardiovascular hierarchy. Induced overexpression experiments and use of fluorescent reporter alleles have shown that *Mesp1* irreversibly promotes cardiovascular progenitor cell fate by directly and/or indirectly regulating the expression of genes involved in epithelial–mesenchymal transition (EMT), as well as the expression of early mesodermal and core cardiac transcription factors (Bondue et al., 2008, 2011; Lindsley et al., 2008; David et al., 2009; Chan et al., 2013; Soibam et al., 2015; den Hartogh et al., 2016). Bipotent cardiopharyngeal progenitor cells with dual cardiac and skeletal muscle potential have recently been identified using this system (Chan et al., 2016). Together, these studies suggest that transient *Mesp1* activity leads to the cell-autonomous activation of a series of context-dependent targets and primes genes for activation after *Mesp1* expression has been down-regulated. This priming by *Mesp1* may occur via the activation of pro-differentiation signaling pathway components, as well as by the direct regulation of target gene chromatin structure (Bondue et al., 2008; Soibam et al., 2015). One *Mesp1* target is *Mesp1* itself; other upstream regulators of *Mesp1* expression in the primitive streak have been identified, including the T-box transcription factors *Brachyury* and *Eomesodermin*, *Oct4*, and components of the canonical Wnt signaling pathway (Liu and Schwartz, 2013). Other genes, including *Mesp2*, are down-regulated on *Mesp1* expression, ensuring unidirectional lineage specification (Bondue et al., 2008). However, the relative roles of *Mesp1* and *Mesp2* in the regulation of cell migratory activity and cell fate specification have remained unclear.

In this issue Chiapparo et al. address this question by comparing the function and targets of *Mesp2* with those of *Mesp1* in differentiating ES cells using an inducible gain-of-function approach. A detailed characterization of the resulting phenotypes revealed that *Mesp1* and *Mesp2* have indistinguishable roles in cardiovascular progenitor cell specification, in the onset of EMT, and in myocardial and endothelial cell differentiation,

© 2016 Kelly This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons license [Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>].

Correspondence to Robert G. Kelly: robert.kelly@univ-amu.fr






Figure 1. **Differential regulation of *Rasgrp3* and *Prickle1* by *Mesp1* and *Mesp2* controls migration speed and directionality of nascent cardiac mesoderm.** A lateral view of an embryonic day (E) 6.5 mouse embryo (left), showing how cells that transiently express *Mesp1* in the primitive streak (PS) migrate (arrows) to form cranial and cardiogenic mesoderm (denoted by the pink and green shaded area). A ventral view of an E7.5 embryo (right) shows differentiated cardiomyocytes in the cardiac crescent (pink), whereas second heart field cells (green), derived from later *Mesp1*-expressing

progenitor cells, retain progenitor cell status and progressively contribute to the elongating heart tube. *Mesp1* and *Mesp2* are both required for cardiovascular progenitor cell specification, EMT, and differentiation. Chiapparo et al. (2016) now identify *Mesp1*-specific targets (*Prickle* and *RasGRP3*) that regulate the speed and polarity of cardiovascular progenitor cell migration in differentiating ES cells. A, anterior; P, posterior.

consistent with previous evidence that *Mesp2* can induce progenitor cell and EMT markers (Lindsley et al., 2008). In contrast *Mesp1*, but not *Mesp2*, is required cell autonomously for rapid progenitor cell migration, monitored using time-lapse microscopy in a monolayer scratch assay. Similarly, *Mesp1* specifically drives the polarized migration of overexpressing cells, accompanied by reorganization of the actin cytoskeleton and the appearance of oriented stress fibers. Importantly, these observations provide a molecular explanation for the phenotypes of *Mesp1* and *Mesp1 Mesp2* double mutant mouse embryos in which progenitor cell migration is impaired and cardiovascular specification is ablated, respectively.

Chiapparo et al. (2016) provide additional molecular insights into *Mesp* protein subfunctionalization by microarray analysis. Numerous commonly regulated genes were identified, with roles in cardiovascular specification and differentiation, as well as in EMT (Fig. 1). The authors focused on two genes, *Rasgrp3* and *Prickle1*, that are differentially regulated by *Mesp1* and *Mesp2* and that might mediate *Mesp1*-specific functions. *Rasgrp3* encodes a guanine nucleotide exchange factor that switches on Ras GTPase activity and downstream extracellular signal-regulated kinase (ERK) signaling. Chiapparo et al. (2016) present evidence that a *Mesp1*-*RasGRP3*-ERK cascade drives the fast migration of *Mesp1*-expressing cells. In support of this, *Rasgrp3* is expressed in mesoderm emerging from the primitive streak, and *Rasgrp3* expression and phospho-ERK levels are reduced in *Mesp1* mutant embryos. Both *Mesp* proteins can bind to target sites in the first intron of *Rasgrp3*, although only *Mesp1* appears to up-regulate *Rasgrp3* transcription, suggesting the existence of yet to be identified *Mesp1*-specific coactivators. *RasGRP3* overexpression in the ES cell differentiation system promotes ERK activation and ERK-dependent migration, although less so than on *Mesp1* expression, indicating that additional targets are required for *Mesp1*-regulated ERK activity. Indeed, *RasGRP3* levels may act together with other inputs, such as FGF-driven ERK activation, to accelerate *Mesp1*-expressing progenitor cell migration. In *Ciona*, *Mesp*-dependent FGF signaling drives cardiopharyngeal progenitor migration by up-regulating the gene that encodes the GTPase RhoDF, promoting actin filament growth and membrane protrusions (Christiaen et al., 2008). Using gene editing in ES cells, Chiapparo et al. (2016) show that *RasGRP3* is required for fast migration after *Mesp1* overexpression. *Rasgrp3* null embryos, however, survive gastrulation, potentially through the activity of other guanine nucleotide exchange factors including additional members of the *Rasgrp* family. Ras activation by *RasGRP3* accompanies angiogenesis and a

Rasgrp3 lacZ gene trap allele has been shown to be expressed at sites of blood vessel formation (Roberts et al., 2004). Furthermore, *RasGRP3* is required for Endothelin stimulated endothelial cell migration, although overexpression of *RasGRP3* in endothelial cells, in contrast to ES cells, affects the direction but not the speed of migration (Randhawa et al., 2011). Future experiments will define whether *RasGRP3* specifically controls migration speed in *Mesp1*-expressing progenitor populations with endothelial fates.

Whereas migration speed is enhanced in *Rasgrp3*-expressing ES cells, Chiapparo et al. (2016) found that the direction of migration is unpolarized in these cells and that the inactivation of *Rasgrp3* does not affect cell polarity after *Mesp1* overexpression. They went on to identify *Prickle1* as a *Mesp1*-specific target that controls the directionality of migration. *Prickle1* is a core component of the planar cell polarity pathway that orients cells within epithelia. Like *Rasgrp3*, *Prickle1* is expressed in cells ingressing through the primitive streak and is decreased in *Mesp1* null embryos. *Mesp1*, but not *Mesp2*, directly binds to target sites in the first intron of *Prickle1*, suggesting that differential DNA binding, as well as different cofactor interactions, may distinguish the two *Mesp* proteins. Overexpression of *Prickle1* in ES cells increased the polarity but not the speed of cardiovascular progenitor cell migration. Loss of *Prickle1* has revealed that it is required before gastrulation for apicobasal polarity of epiblast cells and that its loss is associated with defects in extracellular matrix deposition and spindle orientation (Tao et al., 2009). Interestingly, *Prickle1* has recently been shown to play a later role in heart development. The *Beetlejuice* mutation was identified in an N-ethyl-N-nitrosourea mutagenesis screen as a novel *Prickle1* allele that causes defective development of late-differentiating second heart field cells (Gibbs et al., 2016). In particular, polarized cell orientation and epithelial tissue architecture are lost in the transition zone where differentiation takes place, resulting in a failure of heart tube elongation and congenital heart defects. Consistent with the *Mesp1* study, *Prickle1* was found to specifically regulate directionality of embryonic fibroblast migration in a wound-closure assay. *Prickle1* thus plays iterative roles in the control of cell polarity and migration during heart development.

The dissection of events upstream and downstream of *Mesp1* is proving to be a powerful approach to probe the earliest steps in cranial mesoderm and cardiovascular lineage decisions in vitro and in vivo. In the study by Chiapparo et al. (2016), new insights are provided into cardiovascular progenitor cell biology. These define how intrinsic and extrinsic inputs are integrated to coordinate the specification and migration of nascent

cardiogenic mesoderm in differentiating ES cells. Further work is needed to resolve the sequential sets of direct *Mesp* targets in vivo, as well as the identification of *Mesp* primed genes. This is particularly challenging given the transient expression of endogenous *Mesp1* in different progenitor cell populations. For example, do the *Mesp1* targets identified by Chiapparo et al. (2016) regulate the speed and direction of migration of all, or subsets of, *Mesp1*-expressing cells as they leave the primitive streak? The mechanisms underlying the differential binding and trans-activation properties of the two *Mesp* proteins also remain to be identified. The work of Chiapparo et al. (2016) confirms that progenitor cell migration and specification are separable processes yet coordinated by common transcriptional regulators, consistent with earlier analysis of the single *Mesp* homologue in *Ciona* (Christiaen et al., 2008). Finally, although focused on the earliest events in cardiovascular progenitor cell biology, the study of *Mesp1* function can provide insights that are relevant to regenerative medicine and the etiology of human congenital defects, as pathological variants of *MESP1* have been identified in patients with congenital heart defects (Werner et al., 2016).

Acknowledgments

Work in R.G. Kelly's laboratory is supported by grants from the Fondation pour la Recherche Médicale, Association Française contre les Myopathies, and Fondation Leducq.

The author declares no competing financial interests.

Submitted: 27 April 2016

Accepted: 3 May 2016

References

Bondue, A., G. Lapouge, C. Paulissen, C. Semeraro, M. Iacovino, M. Kyba, and C. Blanpain. 2008. *Mesp1* acts as a master regulator of multipotent cardiovascular progenitor specification. *Cell Stem Cell*. 3:69–84. <http://dx.doi.org/10.1016/j.stem.2008.06.009>

Bondue, A., S. Tännler, G. Chiapparo, S. Chabab, M. Ramialison, C. Paulissen, B. Beck, R. Harvey, and C. Blanpain. 2011. Defining the earliest step of cardiovascular progenitor specification during embryonic stem cell differentiation. *J. Cell Biol.* 192:751–765. <http://dx.doi.org/10.1083/jcb.201007063>

Chan, S.S., X. Shi, A. Toyama, R.W. Arpke, A. Dandapat, M. Iacovino, J. Kang, G. Le, H.R. Hagen, D.J. Garry, and M. Kyba. 2013. *Mesp1* patterns mesoderm into cardiac, hematopoietic, or skeletal myogenic progenitors in a context-dependent manner. *Cell Stem Cell*. 12:587–601. <http://dx.doi.org/10.1016/j.stem.2013.03.004>

Chan, S.S., H.R. Hagen, S.A. Swanson, R. Stewart, K.A. Boll, J. Aho, J.A. Thomson, and M. Kyba. 2016. Development of bipotent cardiac/skeletal myogenic progenitors from *MESP1*+ mesoderm. *Stem Cell Rep.* 6:26–34. <http://dx.doi.org/10.1016/j.stemcr.2015.12.003>

Chiapparo, G., X. Lin, F. Lescroart, S. Chabab, C. Paulissen, L. Pitisci, A. Bondue, and C. Blanpain. 2016. *Mesp1* controls the speed, polarity,

and directionality of cardiovascular progenitor migration. *J. Cell Biol.* <http://dx.doi.org/10.1083/jcb.201505082>

Christiaen, L., B. Davidson, T. Kawashima, W. Powell, H. Nolla, K. Vranizan, and M. Levine. 2008. The transcription/migration interface in cells precursors of *Ciona intestinalis*. *Science*. 320:1349–1352. <http://dx.doi.org/10.1126/science.1158170>

David, R., J. Stieber, E. Fischer, S. Brunner, C. Brenner, S. Pfeiler, F. Schwarz, and W.M. Franz. 2009. Forward programming of pluripotent stem cells towards distinct cardiovascular cell types. *Cardiovasc. Res.* 84:263–272. <http://dx.doi.org/10.1093/cvr/cvp211>

den Hartogh, S.C., K. Wolstencroft, C.L. Mummery, and R. Passier. 2016. A comprehensive gene expression analysis at sequential stages of in vitro cardiac differentiation from isolated *MESP1*-expressing-mesoderm progenitors. *Sci. Rep.* 6:19386. <http://dx.doi.org/10.1038/srep19386>

Gibbs, B.C., R.R. Damerla, E.K. Vldar, B. Chatterjee, Y. Wan, X. Liu, C. Cui, G.C. Gabriel, M. Zahid, H. Yagi, et al. 2016. Prickle1 mutation causes planar cell polarity and directional cell migration defects associated with cardiac outflow tract anomalies and other structural birth defects. *Biol. Open*. 5:323–335. <http://dx.doi.org/10.1242/bio.015750>

Kitajima, S., A. Takagi, T. Inoue, and Y. Saga. 2000. *MesP1* and *MesP2* are essential for the development of cardiac mesoderm. *Development*. 127:3215–3226.

Lescroart, F., S. Chabab, X. Lin, S. Rulands, C. Paulissen, A. Rodolosse, H. Auer, Y. Achouri, C. Dubois, A. Bondue, et al. 2014. Early lineage restriction in temporally distinct populations of *Mesp1* progenitors during mammalian heart development. *Nat. Cell Biol.* 16:829–840. <http://dx.doi.org/10.1038/ncb3024>

Lindsley, R.C., J.G. Gill, T.L. Murphy, E.M. Langer, M. Cai, M. Mashayekhi, W. Wang, N. Niwa, J.M. Nerbonne, M. Kyba, and K.M. Murphy. 2008. *Mesp1* coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs. *Cell Stem Cell*. 3:55–68. <http://dx.doi.org/10.1016/j.stem.2008.04.004>

Liu, Y., and R.J. Schwartz. 2013. Transient *Mesp1* expression: a driver of cardiac cell fate determination. *Transcription*. 4:92–96. <http://dx.doi.org/10.4161/trns.24588>

Randhawa, P.K., S. Rylova, J.Y. Heinz, S. Kiser, J.H. Fried, W.P. Dunworth, A.L. Anderson, A.T. Barber, J.C. Chappell, D.M. Roberts, and V.L. Bautch. 2011. The Ras activator RasGRP3 mediates diabetes-induced embryonic defects and affects endothelial cell migration. *Circ. Res.* 108:1199–1208. <http://dx.doi.org/10.1161/CIRCRESAHA.110.230888>

Roberts, D.M., A.L. Anderson, M. Hidaka, R.L. Swetenburg, C. Patterson, W.L. Stanford, and V.L. Bautch. 2004. A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters. *Mol. Cell Biol.* 24:10515–10528. <http://dx.doi.org/10.1128/MCB.24.24.10515-10528.2004>

Saga, Y., S. Kitajima, and S. Miyagawa-Tomita. 2000. *Mesp1* expression is the earliest sign of cardiovascular development. *Trends Cardiovasc. Med.* 10:345–352. [http://dx.doi.org/10.1016/S1050-1738\(01\)00069-X](http://dx.doi.org/10.1016/S1050-1738(01)00069-X)

Satou, Y., K.S. Imai, and N. Satoh. 2004. The ascidian *Mesp* gene specifies heart precursor cells. *Development*. 131:2533–2541. <http://dx.doi.org/10.1242/dev.01145>

Soibam, B., A. Benham, J. Kim, K.C. Weng, L. Yang, X. Xu, M. Robertson, A. Azares, A.J. Cooney, R.J. Schwartz, and Y. Liu. 2015. Genome-wide identification of *MESP1* targets demonstrates primary regulation over mesendoderm gene activity. *Stem Cells*. 33:3254–3265. <http://dx.doi.org/10.1002/stem.2111>

Tao, H., M. Suzuki, H. Kiyonari, T. Abe, T. Sasaoka, and N. Ueno. 2009. Mouse *prickle1*, the homolog of a PCP gene, is essential for epiblast apical-basal polarity. *Proc. Natl. Acad. Sci. USA*. 106:14426–14431. <http://dx.doi.org/10.1073/pnas.0901332106>

Werner, P., B. Latney, M.A. Deardorff, and E. Goldmuntz. 2016. *MESP1* mutations in patients with congenital heart defects. *Hum. Mutat.* 37:308–314. <http://dx.doi.org/10.1002/humu.22947>